文献速递痛风与晶体性关节病

维立奴拉联合非布司他治疗痛风成人患者:药效学、药代动力学及安全性的IIa期开放标签研究

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study.
PubMed 文献 · RMD Open · 2018-04-09

这项IIa期开放标签多中心研究将64例痛风患者随机分配至5个队列,接受非布司他40或80mg单药或联合维立奴拉2.5-20mg治疗。维立奴拉联合非布司他以剂量依赖方式降低血尿酸,最大降幅52%-82%,而单用非布司他为42%-55%;尿尿酸排泄率联合用药与基线相当,未见药物相互作用,总体耐受良好。

要点

  • 维立奴拉联合非布司他以剂量依赖方式降低血尿酸,40mg非布司他联合组最大降幅52%-77%,单药组42%。
  • 80mg非布司他联合维立奴拉最大降幅62%-82%,单用非布司他55%。
  • 联合用药时尿尿酸排泄率与基线相当,单用非布司他时低于基线,未见药物相互作用。

核心结论

  • 维立奴拉联合非布司他以剂量依赖方式降低血尿酸,同时维持尿尿酸水平与基线相当,这些剂量组合总体耐受良好,支持继续研究口服维立奴拉用于痛风患者。

研究设计与样本

  • IIa期、开放标签、多中心研究,将64例痛风成人患者随机分配至5个队列之一,接受非布司他40或80mg单药或联合维立奴拉2.5-20mg治疗。
  • 系列采集血浆、血清和尿液样本检测维立奴拉和尿酸;通过不良事件、生化面板、心电图和体格检查评估安全性。

主要发现

  • 血清药效学数据显示,血尿酸自基线的最大降幅出现在给药后8-12小时。
  • 维立奴拉联合非布司他40mg时最大降幅为52%-77%,单用非布司他40mg为42%。
  • 维立奴拉联合非布司他80mg时最大降幅为62%-82%,单用非布司他80mg为55%。
  • 单用非布司他时尿尿酸排泄率低于基线,维立奴拉联合非布司他时与基线相当。
  • 维立奴拉血浆暴露随剂量增加,与联合非布司他时相当;未观察到药物相互作用;维立奴拉耐受良好,实验室值无临床意义变化。

关键数值与推荐

  • 维立奴拉联合非布司他40mg最大血尿酸降幅52%-77%,单用非布司他40mg为42%。
  • 维立奴拉联合非布司他80mg最大血尿酸降幅62%-82%,单用非布司他80mg为55%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Verinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for treating gout and asymptomatic hyperuricaemia. This study evaluated the pharmacodynamics, pharmacokinetics and safety of verinurad in combination with febuxostat in adults with gout. METHODS: The phase IIa, open-label, multicentre study randomised 64 subjects into one of five cohorts to receive febuxostat (40 or 80 mg) alone or in combination with verinurad 2.5-20 mg. Serial plasma/serum and urine samples were assayed for verinurad and uric acid. Safety was assessed by adverse events, chemistry panels, ECGs and physical examinations. RESULTS: Serum pharmacodynamic data demonstrated the maximum percent decrease in serum urate (sUA) from baseline (Emax) at 8-12 hours after dosing. Verinurad with febuxostat decreased sUA in a dose-dependent manner. Emax for verinurad with febuxostat 40 mg ranged from 52% to 77% vs 42% for febuxostat 40 mg alone; Emax for verinurad with febuxostat 80 mg was 62%-82% vs 55% for febuxostat 80 mg alone. Urinary uric acid excretion rate was reduced below baseline by febuxostat alone and was comparable to baseline for verinurad with febuxostat. Verinurad plasma exposure increased with dose and was comparable when combined with febuxostat. No drug-drug interactions were observed. Verinurad was well tolerated with no clinically meaningful changes in laboratory values. CONCLUSION: Verinurad administered with febuxostat produced dose-dependent decreases in sUA while maintaining urinary uric acid levels comparable to baseline. These dose combinations of verinurad and febuxostat were generally well tolerated. These data support continued investigation of oral verinurad in patients with gout. TRIAL REGISTRATION NUMBER: NCT02246673.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Fleischmann R, Winkle P, Hall J, et al. Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study. RMD Open. 2018. PMID: 29657831. doi:10.1136/rmdopen-2018-000647

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。